Systemic lupus erythematosus Trials in Warsaw, Poland
Conditions / Systemic lupus erythematosus / Warsaw, Poland
Clinical trials for Systemic lupus erythematosus investigate a range of treatment strategies and patient populations.
48 total trials for this combination
Showing top 10 of 48 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03843125 | A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) | TERMINATED | PHASE3 |
| NCT06617325 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | RECRUITING | — |
| NCT06617325 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | RECRUITING | — |
| NCT04294667 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | COMPLETED | PHASE3 |
| NCT00410384 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus | COMPLETED | PHASE3 |
| NCT04186871 | Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis | COMPLETED | PHASE2 |
| NCT05843643 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | — |
| NCT05617677 | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01196091 | A Study of LY2127399 in Participants With Systemic Lupus Erythematosus | COMPLETED | PHASE3 |
| NCT01408576 | Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus | COMPLETED | PHASE3 |